Results from a 60-sample study assessing the ability to detect EGFR mutations in the plasma and urine in patients with non-small cell lung cancer (NSCLC) using Trovagene's (TROV-3.2%) Precision Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback